Effects of nicorandil on myocardial infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention:study design and protocol for the randomized controlled trial  

作　　者：Xiao-Si JIANG Li-Chao TIAN Zi-Chao JIANG Yu-Ting ZOU Ping LI Xin-Chun YANG Xi SU Jin-Wen TIAN Bei SHI Zong-Zhuang LI Yong-Jun LI Ren-Qiang YANG Geng QIAN Yun-Dai CHEN 

机构地区：[1]Department of Cardiology,the First Medical Center of Chinese PLA General Hospital,Beijing,China [2]The School of Medicine,Nankai University,Tianjin,China [3]Department of Cardiology,the First People's Hospital of Yunlin,Guangxi,China [4]Department of Cardiology,Beijing Chaoyang Hospital,Capital Medical University,Beijing,China [5]Department of Cardiology,Wuhan Asia Heart Hospital,Wuhan,China [6]Department of Cardiology,Hainan Hospital of PLA General Hospital,Hainan,China [7]Department of Cardiology,Affiliated Hospital of Zunyi Medical College,Guizhou,China [8]Department of Cardiology,Guizhou Provincial People's Hospital,Guizhou,China [9]Department of Cardiology,the Second Hospital of Hebei Medical University,Hebei,China [10]Department of Cardiology,the Second Affiliated Hospital of Nanchang University,Jiangxi,China

出　　处：《Journal of Geriatric Cardiology》2020年第8期519-524,共6页老年心脏病学杂志（英文版）

基　　金：supported by the National Key Research and Development program of China(2018ZX09201013);Xinxin Merck Cardiovascular Research Fund(2017-CCA-xinxin merck fund-003)。

摘　　要：Previous studies have shown that nicorandil has a protective effect on cardiomyocytes.However,there is no study to investigate whether perioperative intravenous nicorandil can further reduce the myocardial infarct size in patients with ST-segment elevation myocardial infarction(STEMI)compared to the current standard of percutaneous coronary intervention(PCI)regimen.The CHANGE(China-Administration of Nicorandil Group)study is a multicenter,prospective,randomized,double-blind and parallel-controlled clinical study of STEMI patients undergoing primary PCI in China,aiming to evaluate the efficacy and safety of intravenous nicorandil in ameliorating the myocardial infarct size in STEMI patients undergoing primary PCI and provide evidence-based support for myocardial protection strategies of STEMI patients.

关 键 词：Cardiovascular disease Myocardial infarct size NICORANDIL Primary percutaneous coronary intervention ST-segment elevation myocardial infarction 

分 类 号：R542.22[医药卫生—心血管疾病]